KanonCure Inc. Leveraging the cutting-edge medical research environment in Japan, KanonCure aims to make advancements in healthcare. Based in Yonago, Tottori Prefecture, KanonCure focuses on regenerative medicine and pharmaceuticals for liver diseases, catering to patients with liver cirrhosis who previously had no effective treatment options.

With their proprietary technology using a low-molecular-weight compound called IC-2, KanonCure produces cell sheets that convert mesenchymal stem cells into liver cells. This groundbreaking therapy has obtained 13 patents and offers a safe and direct approach to reducing liver fibrosis. Additionally, KanonCure engages in drug discovery using novel low-molecular-weight compounds to target organ fibrosis, liver cancer, and colorectal cancer.

Their innovative compounds have already acquired substance patents and are in the process of international transition. KanonCure's dedication to advancing medical treatments is showcased through their mission and wide range of products and services